(Reuters) - AstraZeneca will share primary analysis of its COVID-19 vaccine with the most up-to-date data, with an independent panel looking into its U.S. trial, the drugmaker said on Tuesday, following doubts expressed by a U.S health body over the trial data.
The Anglo-Swedish drugmaker said data presented on Monday was based on analysis with a cut-off date of Feb. 17, adding that it had reviewed the preliminary assessment of the primary analysis and found it to be consistent with the interim report.
“We will immediately engage with the independent data safety monitoring board (DSMB) .... We intend to issue results of the primary analysis within 48 hours,” AstraZeneca said.
Reporting by Pushkala Aripaka in Bengaluru; Editing by Anil D’Silva
Our Standards: The Thomson Reuters Trust Principles.